WITHDRAWN: A novel bifunctional T regulatory cell engaging (BiTE) TGF-β1/PD-L1 fusion protein with therapeutic potential for autoimmune diseases

Li, 2017, Drugs for autoimmune inflammatory diseases: From small molecule compounds to anti-TNF biologics, Frontiers in Pharmacology M. Sheth, C.M. Benedum, L.A. Celi, R.G. Mark, N. Markuzon, The association between autoimmune disease and 30-day mortality among sepsis ICU patients: A cohort study, Critical Care. (2019). https://doi.org/10.1186/s13054-019-2357-1. Migita, 2013, Rates of serious intracellular infections in autoimmune disease patients receiving initial glucocorticoid therapy, PLoS ONE, 10.1371/journal.pone.0078699 Hemminki, 2012, Autoimmune disease and subsequent digestive tract cancer by histology, Annals of Oncology A.L. Franks, J.E. Slansky, Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer, Anticancer Research. (2012). K.-H. Yu, C.-F. Kuo, L.H. Huang, W.-K. Huang, L.-C. See, Cancer Risk in Patients With Inflammatory Systemic Autoimmune Rheumatic Diseases, Medicine. (2016). https://doi.org/10.1097/md.0000000000003540. A. Kornbluth, Infliximab Approved for Use in Crohnʼs Disease: A Report on the FDA GI Advisory Committee Conference, Inflammatory Bowel Diseases. (1998). https://doi.org/10.1097/00054725-199811000-00014. P.E. Lipsky, D.M. van der Heijde, E.W. St Clair, D.E. Furst, F.C. Breedveld, J.R. Kalden, J.S. Smolen, M. Weisman, P. Emery, M. Feldmann, G.R. Harriman, R.N. Maini, G. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study, Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.[see comment], New England Journal of Medicine. (2000). Maini, 1999, Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial, Lancet, 10.1016/S0140-6736(99)05246-0 G. Malviya, S. Salemi, B. Laganà, A.P. Diamanti, R. D’Amelio, A. Signore, Biological therapies for rheumatoid arthritis: Progress to date, BioDrugs. (2013). https://doi.org/10.1007/s40259-013-0021-x. Hahn, 2012, American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis, Arthritis Care and Research, 10.1002/acr.21664 Massagué, 2014, TGFbeta signalling in context, Nat Rev Mol Cell Biol, 13, 616, 10.1038/nrm3434 Li, 2007, T Cell-Produced Transforming Growth Factor-β1 Controls T Cell Tolerance and Regulates Th1- and Th17-Cell Differentiation, Immunity, 10.1016/j.immuni.2007.03.014 Varga, 2009, Transforming growth factor β as a therapeutic target in systemic sclerosis, Nature Reviews Rheumatology, 10.1038/nrrheum.2009.26 Bottinger, 1997, Biology of TGF-β in knockout and transgenic mouse models, Kidney International, 10.1038/ki.1997.185 X.J. Wang, D.A. Greenhalgh, J.R. Bickenbach, A. Jiang, D.S. Bundman, T. Krieg, R. Derynck, D.R. Roop, Expression of a dominant-negative type II transforming growth factor β (TGF-β) receptor in the epidermis of transgenic mice blocks TGF-β-mediated growth inhibition, Proceedings of the National Academy of Sciences of the United States of America. (1997). https://doi.org/10.1073/pnas.94.6.2386. Böttinger, 1997, Expression of a dominant-negative mutant TGF-β type II receptor in transgenic mice reveals essential roles for TGF-β in regulation of growth and differentiation in the exocrine pancreas, EMBO Journal, 10.1093/emboj/16.10.2621 Tinoco, 2009, Cell-Intrinsic Transforming Growth Factor-β Signaling Mediates Virus-Specific CD8+ T Cell Deletion and Viral Persistence In Vivo, Immunity, 10.1016/j.immuni.2009.06.015 Budhu, 2017, Blockade of surface-bound TGF-ß on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment, Science Signaling, 10.1126/scisignal.aak9702 Śledzińska, 2013, TGF-β Signalling Is Required for CD4+ T Cell Homeostasis But Dispensable for Regulatory T Cell Function, PLoS Biology, 10.1371/journal.pbio.1001674 Gros, 2008, Cell Intrinsic TGF-β1 Regulation of B Cells, The Journal of Immunology, 10.4049/jimmunol.180.12.8153 MALYGIN, 1993, Regulation of Natural Killer Cell Activity by Transforming Growth Factor‐β and Prostaglandin E2, Scandinavian Journal of Immunology, 10.1111/j.1365-3083.1993.tb01667.x Kubiczkova, 2012, TGF-β - an excellent servant but a bad master, Journal of Translational Medicine, 10.1186/1479-5876-10-183 Bally, 2016, Genetic and Epigenetic Regulation of PD-1 Expression, The Journal of Immunology, 10.4049/jimmunol.1502643 Sampedro-Núñez, 2018, Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors, Scientific Reports, 8, 1, 10.1038/s41598-018-36129-1 Mariotti, 2019, Innate lymphoid cells: Expression of PD-1 and other checkpoints in normal and pathological conditions, Frontiers in Immunology, 10.3389/fimmu.2019.00910 Zamani, 2016, PD-1/PD-L and autoimmunity: A growing relationship, Cellular Immunology, 310, 27, 10.1016/j.cellimm.2016.09.009 Nishimura, 1999, Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor, Immunity, 10.1016/S1074-7613(00)80089-8 Mahoney, 2015, The next immune-checkpoint inhibitors: Pd-1/pd-l1 blockade in melanoma, Clinical Therapeutics, 10.1016/j.clinthera.2015.02.018 Akinleye, 2019, Immune checkpoint inhibitors of PD-L1 as cancer therapeutics, Journal of Hematology and Oncology, 12, 1, 10.1186/s13045-019-0779-5 De Sousa Linhares, 2019, Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling, Scientific Reports, 9, 1, 10.1038/s41598-019-47910-1 Smits, 2016, Bispecific T-cell engagers (BiTES) as treatment of B-cell lymphoma, Journal of Clinical Oncology, 10.1200/JCO.2015.64.9970 Hagness, 2012, Kinetics and Activation Requirements of Contact-Dependent Immune Suppression by Human Regulatory T Cells, The Journal of Immunology, 10.4049/jimmunol.1101367 Arce-Sillas, 2016, Regulatory T Cells: Molecular Actions on Effector Cells in Immune Regulation, Journal of Immunology Research, 10.1155/2016/1720827 Von Boehmer, 2013, Therapeutic opportunities for manipulating TReg cells in autoimmunity and cancer, Nature Reviews Drug Discovery, 10.1038/nrd3683 Sharma, 2018, Emerging functions of regulatory T cells in tissue homeostasis, Frontiers in Immunology, 10.3389/fimmu.2018.00883 Esensten, 2018, Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier, Journal of Allergy and Clinical Immunology, 10.1016/j.jaci.2018.10.015 Dhabaria, 2015, A High-Efficiency Cellular Extraction System for Biological Proteomics, Journal of Proteome Research, 10.1021/acs.jproteome.5b00547 De los Santos, 2019, Cellular Retention Assay to Determine the Interaction Frequency of CD19-directed Chimeric Antigen Receptor (CAR) Engineered Cells against CD19+ Leukemic Cells, Bio-Protocol, 9, 1, 10.21769/BioProtoc.3358 J.S. Huston, D. Levinson, M. Mudgett-Hunter, M.S. Tai, J. Novotny, M.N. Margolies, R.J. Ridge, R.E. Bruccoleri, E. Haber, R. Crea, H. Oppermann, Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli, Proceedings of the National Academy of Sciences of the United States of America. (1988). https://doi.org/10.1073/pnas.85.16.5879. Chen, 2013, Fusion protein linkers: Property, design and functionality, Advanced Drug Delivery Reviews, 10.1016/j.addr.2012.09.039 Kelley, 2015, The Phyre2 web portal for protein modeling, prediction and analysis, Nature Protocols, 10.1038/nprot.2015.053 Lin, 2006, The structural basis of TGF-β, bone morphogenetic protein, and activin ligand binding, Reproduction, 10.1530/rep.1.01072 Yamashita, 1994, Formation of hetero-oligomeric complexes of type I and type II receptors for transforming growth factor-β, Journal of Biological Chemistry Radaev, 2010, Ternary complex of transforming growth factor-β1 reveals isoform-specific ligand recognition and receptor recruitment in the superfamily, Journal of Biological Chemistry, 10.1074/jbc.M109.079921 Tabe, 2012, TGF-β1 Supports Leukemia Cell Survival Via Negative Regulation of FLI-1 Transcription Factor, ERK Inactivation and MMP-1 Secretion, Blood, 10.1182/blood.V120.21.3543.3543 Sun, 2013, Regulation of nuclear factor-κB in autoimmunity, Trends in Immunology, 10.1016/j.it.2013.01.004 Miraghazadeh, 2018, Nuclear factor-kappaB in autoimmunity: Man and mouse, Frontiers in Immunology, 10.3389/fimmu.2018.00613 Langer, 2018, Neither Lys- and DAP-type peptidoglycans stimulate mouse or human innate immune cells via Toll-like receptor 2, PLoS ONE, 10.1371/journal.pone.0193207 Zuazo, 2017, Molecular mechanisms of programmed cell death-1 dependent T cell suppression: Relevance for immunotherapy, Annals of Translational Medicine, 10.21037/atm.2017.06.11 Meng, 2010, Association of Shp2 with phosphorylated IL-22R1 is required for interleukin-22-induced MAP kinase activation, Journal of Molecular Cell Biology, 10.1093/jmcb/mjq017 Zhu, 2011, Kit-Shp2-Kit signaling acts to maintain a functional hematopoietic stem and progenitor cell pool, Blood Park, 2017, Reciprocal regulation of TLR2-mediated IFN-β production by SHP2 and Gsk3β, Scientific Reports Hl, 1999, Activators and target genes of Rel/NF-kappaB transcription factors, Oncogene, 18, 6853, 10.1038/sj.onc.1203239 B. V. Park, Z.T. Freeman, A. Ghasemzadeh, M.A. Chattergoon, A. Rutebemberwa, J. Steigner, M.E. Winter, T. V. Huynh, S.M. Sebald, S.J. Lee, F. Pan, D.M. Pardoll, A.L. Cox, TGFβ1-mediated SMAD3 enhances PD-1 expression on antigen-specific T cells in cancer, Cancer Discovery. (2016). https://doi.org/10.1158/2159-8290.CD-15-1347. Giroux, 2010, T Cell Activation Leads to Protein Kinase Cθ-Dependent Inhibition of TGF-β Signaling, The Journal of Immunology, 10.4049/jimmunol.1000137 Sun, 2017, A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer, Oncotarget, 8, 29067, 10.18632/oncotarget.16173 Yang, 2008, PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro, Investigative Ophthalmology and Visual Science, 10.1167/iovs.07-1606 Zhang, 1998, Regulation of the activity of IFN-γ promoter elements during Th cell differentiation, Journal of Immunology, 10.4049/jimmunol.161.11.6105 Girdlestone, 1996, Autocrine activation by interferon-γ of STAT factors following T cell activation, European Journal of Immunology, 10.1002/eji.1830260329 A.N. Shatrova, E. V. Mityushova, N.A. Aksenov, I.I. Marakhova, CD25 expression on the surface of Jurkat cells, Cell and Tissue Biology. (2015). https://doi.org/10.1134/S1990519X15050119. Castiglioni, 2017, Femtograms of interferon-γ suffice to modulate the behavior of jurkat cells: A new light in immunomodulation, International Journal of Molecular Sciences, 10.3390/ijms18122715 Lin, 2013, The talented interferon-gamma, Advances in Bioscience and Biotechnology, 10.4236/abb.2013.47A3002 Valentine, 1985, Phytohemagglutinin binds to the 20‐kDa molecule of the T3 complex, European Journal of Immunology, 10.1002/eji.1830150821 T. Liu, L. Zhang, D. Joo, S.C. Sun, NF-κB signaling in inflammation, Signal Transduction and Targeted Therapy. (2017). https://doi.org/10.1038/sigtrans.2017.23. Gerondakis, 2010, Roles of the NF-kappaB pathway in lymphocyte development and function, Cold Spring Harbor Perspectives in Biology, 10.1101/cshperspect.a000182 Wu, 2015, Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia, Journal of Hematology and Oncology, 10.1186/s13045-015-0195-4 Ross, 2017, Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing, PLoS ONE, 10.1371/journal.pone.0183390 Marie, 2005, TGF-β1 maintains suppressor function and Foxp3 expression in CD4 +CD25+ regulatory T cells, Journal of Experimental Medicine, 10.1084/jem.20042276 Chen, 2010, TGF-β and ’adaptive ’Foxp3+ regulatory T cells, Journal of Molecular Cell Biology, 10.1093/jmcb/mjp004 M. Wong, A. La Cava, B.H. Hahn, I.M. Rheumatology, PD-1 Signaling Promotes Suppressive Function of CD4 + Regulatory T Cells in ( New Zealand Black x New Zealand White ) F 1 Lupus-Prone Mice in a Dose-Dependent Manner, (n.d.) 3–4. Han, 2019, Turning the tide against regulatory T cells, Frontiers in Oncology, 10.3389/fonc.2019.00279 Gianchecchi, 2018, Inhibitory receptors and pathways of lymphocytes: The role of PD-1 in Treg development and their involvement in autoimmunity onset and cancer progression, Frontiers in Immunology, 10.3389/fimmu.2018.02374 Flanders, 2003, Medical applications of transforming growth factor-beta, Clinical Medicine & Research, 10.3121/cmr.1.1.13 Marafini, 2013, TGF-Beta Signaling Manipulation as Potential Therapy for IBD, Current Drug Targets, 10.2174/13894501113149990157 H. Ishigame, L.A. Zenewicz, S. Sanjabi, P. Licona-Limóa, M. Nakayama, W.J. Leonard, R.A. Flavell, Excessive Th1 responses due to the absence of TGF-β signaling cause autoimmune diabetes and dysregulated Treg cell homeostasis, Proceedings of the National Academy of Sciences of the United States of America. (2013). https://doi.org/10.1073/pnas.1304498110. Becker-Merok, 2010, Levels of transforming growth factor-β are low in systemic lupus erythematosus patients with active disease, Journal of Rheumatology, 10.3899/jrheum.100180 Herrington, 2016, Modulation of NF-κB Signaling as a Therapeutic Target in Autoimmunity, Journal of Biomolecular Screening, 10.1177/1087057115617456 Ai, 2013, Optimal method to stimulate cytokine production and its use in immunotoxicity assessment, International Journal of Environmental Research and Public Health, 10.3390/ijerph10093834 Kim, 2006, Quantitative Analysis of Phosphotyrosine Signaling Networks Triggered by CD3 and CD28 Costimulation in Jurkat Cells, The Journal of Immunology, 10.4049/jimmunol.176.5.2833 Schmidt, 2012, Molecular mechanisms oftreg-mediatedt cell suppression, Frontiers in Immunology, 10.3389/fimmu.2012.00051 Janikashvili, 2016, Immunotherapeutic Targeting in Autoimmune Diseases, Mediators of Inflammation, 2 Tran, 2012, TGF-β: The sword, the wand, and the shield of FOXP3 + regulatory T cells, Journal of Molecular Cell Biology, 10.1093/jmcb/mjr033 P.H. Jeon, K.I. Oh, IL2 is required for functional maturation of regulatory T cells, Animal Cells and Systems. (2017). https://doi.org/10.1080/19768354.2016.1272489. Herppich, 2019, Dynamic Imprinting of the Treg Cell-Specific Epigenetic Signature in Developing Thymic Regulatory T Cells, Frontiers in Immunology, 10.3389/fimmu.2019.02382 Beriou, 2010, TGF-β Induces IL-9 Production from Human Th17 Cells, The Journal of Immunology, 10.4049/jimmunol.1000356 D.E. Smilek, M.R. Ehlers, G.T. Nepom, Restoring the balance: Immunotherapeutic combinations for autoimmune disease, DMM Disease Models and Mechanisms. (2014). https://doi.org/10.1242/dmm.015099. Löffek, 2018, Transforming of the Tumor Microenvironment: Implications for TGF-β Inhibition in the Context of Immune-Checkpoint Therapy, Journal of Oncology, 2018 Wang, 2008, Protective role of programmed death 1 ligand 1 (PD-L1) in nonobese diabetic mice: The paradox in transgenic models, Diabetes, 10.2337/db07-1260 2019, Nature Biomedical Engineering, 3 McNamee, 2017, Timelines of translational science: From technology initiation to FDA approval, PLoS ONE, 10.1371/journal.pone.0177371 Vincent, 2000, Molecular targets for autoimmune and genetic disorders of neuromuscular transmission, European Journal of Biochemistry, 10.1046/j.1432-1033.2000.01785.x Pérez-De-Lis, 2017, Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry), Expert Opinion on Drug Safety, 10.1080/14740338.2017.1372421 Le Rouzic, 2017, Th17 cytokines: Novel potential therapeutic targets for COPD pathogenesis and exacerbations, European Respiratory Journal, 10.1183/13993003.02434-2016